AnaptysBio, Inc. (FRA:AN6)

Market Cap	1.43B +201.3%
Revenue (ttm)	199.81M +157.0%
Net Income	-11.27M
EPS	-0.39
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	18
Open	56.00
Previous Close	56.00
Day's Range	49.80 - 56.00
52-Week Range	13.90 - 58.00
Beta	n/a
RSI	45.61
Earnings Date	May 8, 2026

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 104
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AN6

Financial Performance

In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.

Financial numbers in USD